Former SVP & Chief Financial Officer · Vertex Pharmaceuticals Inc (VRTX)

Thomas Graney

A named executive officer of Vertex Pharmaceuticals in every fiscal year CompBrief holds from FY2017 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$2,937,685

Salary $550,000Stock awards $1,400,130

FY2017: $1,927,400

7th of 7 named executive officers at Vertex Pharmaceuticals by FY2018 total.

7 named officers on file for Vertex Pharmaceuticals, FY2018

Thomas Graney’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing
  • VRTX’s disclosed peer group of 12 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Vertex Pharmaceuticals’s whole pay program stands against its peers

  • Vertex Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VRTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2019 (DEF 14A).

Free

Get Thomas Graney’s full pay file as a PDF — free

More than this page: up to 10 years of Thomas’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Thomas Graney compensation by year

Vertex Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as Vertex Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018
Salary$154,423$550,000
Bonus$150,000$0
Stock awards$1,500,140$1,400,130
Option awards$0$606,332
Non-equity incentive$110,392$367,538
Pension and deferred compensation$0$0
All other$12,445$13,685
Total$1,927,400$2,937,685

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vertex Pharmaceuticals Inc DEF 14A filed April 26, 2019, accession 0001308179-19-000189, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Vertex Pharmaceuticals Inc filed document, accession 0001308179-19-000189. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2019.

$1.9M
$2.9M
FY17
FY18
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
RSU4,783$792,591—
RSU4,500$745,695—
RSU2,250$372,848—
PSU2,250$372,848—
Option8,480—$155.57

Per the Outstanding Equity Awards at Fiscal Year-End table in Vertex Pharmaceuticals Inc's FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Vertex Pharmaceuticals’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Jeffrey LeidenChairman, President & CEO$18,799,147
Jeffrey ChodakewitzFormer EVP & Chief Medical Officer$5,696,996
Amit SachdevEVP & Chief Regulatory Officer$5,678,261
Michael PariniEVP & Chief Legal and Administrative Officer$5,372,336
Stuart ArbuckleEVP & Chief Commercial Officer$5,347,092
Ian SmithFormer EVP & Chief Operating Officer and Former Interim Chief Financial Officer$4,626,134
Thomas Graney · this pageFormer SVP & Chief Financial Officer$2,937,685

The full Vertex Pharmaceuticals compensation record

free company brief

This page is one person within Vertex Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Vertex Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vertex Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Thomas Graney's compensation dossier · One-time report. No refunds.